Movelax - Pharmacology: Produces increased osmotic pressure within colon and acidifies its contents, resulting in increased stool water content and stool softening. Causes migration of ammonia from blood into colon, where it is converted to ammonium ion and expelled through laxative action.
Indication: Treatment of constipation; prevention and treatment of portal-systemic encephalopathy, including stages of hepatic precoma and coma.
Movelax is a type of sugar. It is broken down in the large intestine into mild acids that draw water into the colon, which helps soften the stools.
Movelax is used to treat chronic constipation.
Movelax may also be used for other purposes not listed in this medication guide.
Therapeutically, Movelax has laxative and ammonia-detoxifying actions. In treating constipation Movelax metabolites draw water into the bowel, causing a cathartic effect through osmotic action.
Indication: For the treatment of constipation and hepatic encephalopathy.
Adult: Initially, 10-20 g (15-30 ml) daily as a single dose or in 2 divided doses; gradually adjust according to patient's response. Max dose: 45 ml (or up to 40 g of the reconstituted oral powder formulation)/day.
Child: As 3.35 mg/5 ml solution: 1 mth to 1 yr: 2.5 ml; 1-5 yr: 5 ml; 5-10 yr: 10 ml; 10-18 yr: 15 ml. All doses to be given bid. Oral hepatic encephalopathy
Adult: 60-100 g (90-150 ml) daily in 3 divided doses; adjust to produce 2 or 3 soft stools each day. Rectal hepatic encephalopathy
Adult: Mix 200 g (300 ml) with 700 ml water or 0.9% sodium chloride as a retention enema. Retain enema for 30-60 minutes; repeat every 4-6 hr until oral medication can be administered.
Adult: PO Constipation Initial: 10-20 g (15-30 mL)/day. Max: 45 mL (or 40 g of the reconstituted oral formulation)/day. Hepatic encephalopathy 60-100 g (90-150 mL)/day in 3 divided doses; adjust accordingly. Rectal Hepatic encephalopathy Mix 200 g (300 mL w/ 700 mL water or 0.9% NaCl as a retention enema. Retain enema for 30-60 mins; repeat 4-6 hrly until oral medication can be administered.
Hyperammonaemia in liver diseases. Hepatic coma. Chronic constipation. Dysbacteria e.g. in Salmonella carriers or following antibiotic treatment. Periodontal disease.